CANCER:

Melanoma

Related cancers:

‹

Ocular Melanoma (84)

Uveal Melanoma (81)

Cutaneous Melanoma (74)

Mucosal Melanoma (26)

Ocular Melanoma (84)

Uveal Melanoma (81)

Cutaneous Melanoma (74)

Mucosal Melanoma (26)

›

BRAF mutation BRAF mutation	Mucosal Melanoma Mucosal Melanoma	PD1 inhibitor Sensitive: C3 – Early Trials Front Immunol - 3 weeks
KIT mutation KIT mutation	Mucosal Melanoma Mucosal Melanoma	PD1 inhibitor Sensitive: C3 – Early Trials Front Immunol - 3 weeks
NRAS mutation NRAS mutation	Cutaneous Melanoma Cutaneous Melanoma	PD1 inhibitor Resistant: C3 – Early Trials Front Immunol - 3 weeks
BRAF mutation BRAF mutation	Cutaneous Melanoma Cutaneous Melanoma	PD1 inhibitor Resistant: C3 – Early Trials Front Immunol - 3 weeks
NRAS mutation NRAS mutation	Mucosal Melanoma Mucosal Melanoma	PD1 inhibitor Resistant: C3 – Early Trials Front Immunol - 3 weeks
KIT mutation KIT mutation	Cutaneous Melanoma Cutaneous Melanoma	PD1 inhibitor Sensitive: C3 – Early Trials Front Immunol - 3 weeks
BRAF V600 BRAF V600	Melanoma Melanoma	vemurafenib + atezolizumab + cobimetinib Sensitive: A1 - Approval
BRAF V600E BRAF V600E	Melanoma Melanoma	dabrafenib Sensitive: A1 - Approval
BRAF V600E BRAF V600E	Melanoma Melanoma	trametinib + dabrafenib Sensitive: A1 - Approval
BRAF V600 BRAF V600	Melanoma Melanoma	encorafenib + binimetinib Sensitive: A1 - Approval
BRAF V600K BRAF V600K	Melanoma Melanoma	trametinib + dabrafenib Sensitive: A1 - Approval
No biomarker No biomarker	Melanoma Melanoma	pembrolizumab Sensitive: A1 - Approval
BRAF V600E BRAF V600E	Melanoma Melanoma	vemurafenib + cobimetinib Sensitive: A1 - Approval
BRAF V600 BRAF V600	Melanoma Melanoma	vemurafenib + cobimetinib Sensitive: A1 - Approval
BRAF V600E BRAF V600E	Melanoma Melanoma	vemurafenib Sensitive: A1 - Approval
BRAF V600E BRAF V600E	Melanoma Melanoma	trametinib Sensitive: A1 - Approval
No biomarker No biomarker	Melanoma Melanoma	nivolumab Sensitive: A1 - Approval
No biomarker No biomarker	Melanoma Melanoma	ipilimumab Sensitive: A1 - Approval
No biomarker No biomarker	Melanoma Melanoma	nivolumab + ipilimumab Sensitive: A1 - Approval
PD-L1 underexpression PD-L1 underexpression	Melanoma Melanoma	ipilimumab Sensitive: A1 - Approval
PD-L1 underexpression PD-L1 underexpression	Melanoma Melanoma	nivolumab + ipilimumab Sensitive: A1 - Approval
BRAF V600 BRAF V600	Melanoma Melanoma	dabrafenib Sensitive: A1 - Approval
No biomarker No biomarker	Melanoma Melanoma	trametinib Resistant: A1 - Approval
BRAF V600 BRAF V600	Melanoma Melanoma	trametinib + dabrafenib Sensitive: A1 - Approval
BRAF V600 BRAF V600	Melanoma Melanoma	trametinib Sensitive: A1 - Approval
BRAF V600K BRAF V600K	Melanoma Melanoma	trametinib Sensitive: A1 - Approval
BRAF V600 BRAF V600	Melanoma Melanoma	vemurafenib Sensitive: A1 - Approval
No biomarker No biomarker	Cutaneous Melanoma Cutaneous Melanoma	ipilimumab Sensitive: A1 - Approval
BRAF V600K BRAF V600K	Melanoma Melanoma	encorafenib + binimetinib Sensitive: A1 - Approval
BRAF V600E BRAF V600E	Melanoma Melanoma	encorafenib + binimetinib Sensitive: A1 - Approval
BRAF V600K BRAF V600K	Melanoma Melanoma	vemurafenib + cobimetinib Sensitive: A1 - Approval
LDH elevation LDH elevation	Melanoma Melanoma	nivolumab + ipilimumab Sensitive: A1 - Approval
No biomarker No biomarker	Melanoma Melanoma	aldesleukin Sensitive: A1 - Approval
No biomarker No biomarker	Cutaneous Melanoma Cutaneous Melanoma	TC Sensitive: A2 - Guideline
No biomarker No biomarker	Uveal Melanoma Uveal Melanoma	TC Sensitive: A2 - Guideline
No biomarker No biomarker	Uveal Melanoma Uveal Melanoma	pembrolizumab Sensitive: A2 - Guideline
No biomarker No biomarker	Uveal Melanoma Uveal Melanoma	nivolumab Sensitive: A2 - Guideline
No biomarker No biomarker	Uveal Melanoma Uveal Melanoma	ipilimumab Sensitive: A2 - Guideline
No biomarker No biomarker	Uveal Melanoma Uveal Melanoma	dacarbazine Sensitive: A2 - Guideline
No biomarker No biomarker	Uveal Melanoma Uveal Melanoma	temozolomide Sensitive: A2 - Guideline
BRAF V600 BRAF V600	Cutaneous Melanoma Cutaneous Melanoma	trametinib Resistant: A2 - Guideline
BRAF V600 BRAF V600	Cutaneous Melanoma Cutaneous Melanoma	vemurafenib + atezolizumab + cobimetinib Sensitive: A2 - Guideline
No biomarker No biomarker	Cutaneous Melanoma Cutaneous Melanoma	paclitaxel Sensitive: A2 - Guideline
No biomarker No biomarker	Cutaneous Melanoma Cutaneous Melanoma	albumin-bound paclitaxel Sensitive: A2 - Guideline
No biomarker No biomarker	Cutaneous Melanoma Cutaneous Melanoma	temozolomide Sensitive: A2 - Guideline
No biomarker No biomarker	Cutaneous Melanoma Cutaneous Melanoma	dacarbazine Sensitive: A2 - Guideline
No biomarker No biomarker	Cutaneous Melanoma Cutaneous Melanoma	nivolumab + ipilimumab Sensitive: A2 - Guideline
No biomarker No biomarker	Uveal Melanoma Uveal Melanoma	trametinib Sensitive: A2 - Guideline
No biomarker No biomarker	Uveal Melanoma Uveal Melanoma	paclitaxel Sensitive: A2 - Guideline
No biomarker No biomarker	Uveal Melanoma Uveal Melanoma	albumin-bound paclitaxel Sensitive: A2 - Guideline
No biomarker No biomarker	Uveal Melanoma Uveal Melanoma	nivolumab + ipilimumab Sensitive: A2 - Guideline
No biomarker No biomarker	Cutaneous Melanoma Cutaneous Melanoma	pembrolizumab + ipilimumab Sensitive: A2 - Guideline
BRAF mutation BRAF mutation	Melanoma Melanoma	dabrafenib + granisetron intravenous Sensitive: A2 - Guideline
BRAF V600 BRAF V600	Cutaneous Melanoma Cutaneous Melanoma	vemurafenib + cobimetinib Sensitive: A2 - Guideline
BRAF V600E BRAF V600E	Cutaneous Melanoma Cutaneous Melanoma	trametinib + dabrafenib Sensitive: A2 - Guideline
NRAS mutation NRAS mutation	Melanoma Melanoma	binimetinib Sensitive: A2 - Guideline
BRAF V600 BRAF V600	Cutaneous Melanoma Cutaneous Melanoma	encorafenib + binimetinib Sensitive: A2 - Guideline
BRAF V600 BRAF V600	Melanoma Melanoma	BRAF inhibitor + MEK inhibitor Sensitive: A2 - Guideline
NTRK1 fusion NTRK1 fusion	Melanoma Melanoma	larotrectinib Sensitive: A2 - Guideline
NTRK3 fusion NTRK3 fusion	Melanoma Melanoma	larotrectinib Sensitive: A2 - Guideline
NTRK2 fusion NTRK2 fusion	Melanoma Melanoma	larotrectinib Sensitive: A2 - Guideline
BRAF V600 BRAF V600	Cutaneous Melanoma Cutaneous Melanoma	dabrafenib + SNR1611 Sensitive: A2 - Guideline
BRAF V600 BRAF V600	Cutaneous Melanoma Cutaneous Melanoma	nivolumab + ipilimumab Sensitive: A2 - Guideline
BRAF V600K BRAF V600K	Cutaneous Melanoma Cutaneous Melanoma	trametinib + dabrafenib Sensitive: A2 - Guideline
BRAF V600K BRAF V600K	Cutaneous Melanoma Cutaneous Melanoma	pembrolizumab Sensitive: A2 - Guideline
BRAF V600E BRAF V600E	Cutaneous Melanoma Cutaneous Melanoma	pembrolizumab Sensitive: A2 - Guideline
BRAF V600K BRAF V600K	Cutaneous Melanoma Cutaneous Melanoma	nivolumab Sensitive: A2 - Guideline
BRAF V600E BRAF V600E	Cutaneous Melanoma Cutaneous Melanoma	nivolumab Sensitive: A2 - Guideline
No biomarker No biomarker	Cutaneous Melanoma Cutaneous Melanoma	nivolumab Sensitive: A2 - Guideline
No biomarker No biomarker	Cutaneous Melanoma Cutaneous Melanoma	pembrolizumab Sensitive: A2 - Guideline
ROS1 fusion ROS1 fusion	Melanoma Melanoma	entrectinib Sensitive: A2 - Guideline
KIT exon 11 mutation KIT exon 11 mutation	Melanoma Melanoma	sunitinib Sensitive: A2 - Guideline
KIT exon 11 mutation KIT exon 11 mutation	Melanoma Melanoma	nilotinib Sensitive: A2 - Guideline
KIT exon 13 mutation KIT exon 13 mutation	Melanoma Melanoma	sunitinib Sensitive: A2 - Guideline
BRAF V600K BRAF V600K	Melanoma Melanoma	dabrafenib Sensitive: A2 - Guideline
TMB-H TMB-H	Melanoma Melanoma	nivolumab + ipilimumab Sensitive: A2 - Guideline
ROS1 fusion ROS1 fusion	Melanoma Melanoma	crizotinib Sensitive: A2 - Guideline
NTRK3 fusion NTRK3 fusion	Melanoma Melanoma	entrectinib Sensitive: A2 - Guideline
NTRK1 fusion NTRK1 fusion	Melanoma Melanoma	entrectinib Sensitive: A2 - Guideline
KIT exon 13 mutation KIT exon 13 mutation	Melanoma Melanoma	nilotinib Sensitive: A2 - Guideline
BRAF fusion BRAF fusion	Melanoma Melanoma	sorafenib Sensitive: A2 - Guideline
ALK fusion ALK fusion	Melanoma Melanoma	crizotinib Sensitive: A2 - Guideline
ALK fusion ALK fusion	Melanoma Melanoma	entrectinib Sensitive: A2 - Guideline
BRAF V600 BRAF V600	Cutaneous Melanoma Cutaneous Melanoma	pembrolizumab + dabrafenib Sensitive: A2 - Guideline
No biomarker No biomarker	Cutaneous Melanoma Cutaneous Melanoma	talimogene laherparepvec Sensitive: A2 - Guideline
No biomarker No biomarker	Cutaneous Melanoma Cutaneous Melanoma	CaT Sensitive: A2 - Guideline
No biomarker No biomarker	Cutaneous Melanoma Cutaneous Melanoma	paclitaxel + albumin-bound paclitaxel + dacarbazine Sensitive: A2 - Guideline
No biomarker No biomarker	Cutaneous Melanoma Cutaneous Melanoma	CVD Sensitive: A2 - Guideline
BRAF V600E BRAF V600E	Cutaneous Melanoma Cutaneous Melanoma	encorafenib + binimetinib Sensitive: A2 - Guideline
BRAF V600K BRAF V600K	Cutaneous Melanoma Cutaneous Melanoma	encorafenib + binimetinib Sensitive: A2 - Guideline
BRAF V600E BRAF V600E	Cutaneous Melanoma Cutaneous Melanoma	vemurafenib + cobimetinib Sensitive: A2 - Guideline
BRAF V600E BRAF V600E	Cutaneous Melanoma Cutaneous Melanoma	dabrafenib Sensitive: A2 - Guideline
BRAF V600E BRAF V600E	Cutaneous Melanoma Cutaneous Melanoma	vemurafenib Sensitive: A2 - Guideline
BRAF V600 BRAF V600	Cutaneous Melanoma Cutaneous Melanoma	pembrolizumab + trametinib Sensitive: A2 - Guideline
No biomarker No biomarker	Cutaneous Melanoma Cutaneous Melanoma	PD1 inhibitor + talimogene laherparepvec Resistant: A2 - Guideline
No biomarker No biomarker	Cutaneous Melanoma Cutaneous Melanoma	ipilimumab + talimogene laherparepvec Sensitive: A2 - Guideline
NTRK2 fusion NTRK2 fusion	Cutaneous Melanoma Cutaneous Melanoma	entrectinib Sensitive: A2 - Guideline
NTRK1 fusion NTRK1 fusion	Cutaneous Melanoma Cutaneous Melanoma	entrectinib Sensitive: A2 - Guideline

Melanoma

Associations(851)

Associations
(851)